These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39327962)

  • 1. [Analysis of predictive effect of European treatment and outcome study long term survival score on survival outcomes in children with chronic myeloid leukemia of chronic phase].
    Zheng FY; Deng RZ; Lu AD; Jia YP; Zeng HM; Zhang LP; Jiang Q
    Zhonghua Er Ke Za Zhi; 2024 Oct; 62(10):956-961. PubMed ID: 39327962
    [No Abstract]   [Full Text] [Related]  

  • 2. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Zhang XS; Gale RP; Huang XJ; Jiang Q
    Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
    Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
    Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy].
    Li ZY; Zhang MY; Zhang XS; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):106-111. PubMed ID: 36948863
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.
    Nicolini FE; Alcazer V; Cony-Makhoul P; Heiblig M; Morisset S; Fossard G; Bidet A; Schmitt A; Sobh M; Hayette S; Mahon FX; Dulucq S; Etienne G
    Exp Hematol; 2018 Aug; 64():97-105.e4. PubMed ID: 29800673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
    Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
    Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
    Iriyama N; Iwanaga E; Kimura Y; Watanabe N; Ishikawa M; Nakayama H; Sato E; Tabayashi T; Mitsumori T; Takaku T; Nakazato T; Tokuhira M; Fujita H; Ando M; Hatta Y; Kawaguchi T
    Int J Hematol; 2024 Jul; 120(1):60-70. PubMed ID: 38587692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome prediction of chronic myeloid leukemia (CML) in children.
    Leung WY; Cheuk DK; Cheng FW; Leung AW; Chiu KH; Ho KK; Li CH; Chan GC
    Ann Hematol; 2022 Aug; 101(8):1677-1688. PubMed ID: 35641639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
    Zhang XS; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):54-62. PubMed ID: 35231994
    [No Abstract]   [Full Text] [Related]  

  • 13. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
    Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
    Wang PP; Zhang PP; Zhang J; Xi YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):723-728. PubMed ID: 31204922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic analysis of chronic myeloid leukemia with Cox model and the Sokal, Hasford score].
    Gan DY; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):662-6. PubMed ID: 16928295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.
    Clark RE; Apperley JF; Copland M; Cicconi S
    Blood Adv; 2021 Feb; 5(4):1102-1109. PubMed ID: 33616651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
    Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients.
    Towachiraporna S; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Tantiworawit A
    Asian Pac J Cancer Prev; 2023 May; 24(5):1513-1520. PubMed ID: 37247270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.